Cardiac fibrosis
Open accessThe DOI matches its Crossref record; 612 of the 615 references it cites were found in a registry or an index.
Abstract
Myocardial fibrosis, the expansion of the cardiac interstitium through deposition of extracellular matrix proteins, is a common pathophysiologic companion of many different myocardial conditions. Fibrosis may reflect activation of reparative or maladaptive processes. Activated fibroblasts and myofibroblasts are the central cellular effectors in cardiac fibrosis, serving as the main source of matrix proteins. Immune cells, vascular cells and cardiomyocytes may also acquire a fibrogenic phenotype under conditions of stress, activating fibroblast populations. Fibrogenic growth factors (such as transforming growth factor-β and platelet-derived growth factors), cytokines [including tumour necrosis factor-α, interleukin (IL)-1, IL-6, IL-10, and IL-4], and neurohumoral pathways trigger fibrogenic signalling cascades through binding to surface receptors, and activation of downstream signalling cascades. In addition, matricellular macromolecules are deposited in the remodelling myocardium and regulate matrix assembly, while modulating signal transduction cascades and protease or growth factor activity. Cardiac fibroblasts can also sense mechanical stress through mechanosensitive receptors, ion channels and integrins, activating intracellular fibrogenic cascades that contribute to fibrosis in response to pressure overload. Although subpopulations of fibroblast-like cells may exert important protective actions in both reparative and interstitial/perivascular fibrosis, ultimately fibrotic changes perturb systolic and diastolic function, and may play an important role in the pathogenesis of arrhythmias. This review article discusses the molecular mechanisms involved in the pathogenesis of cardiac fibrosis in various myocardial diseases, including myocardial infarction, heart failure with reduced or preserved ejection fraction, genetic cardiomyopathies, and diabetic heart disease. Development of fibrosis-targeting therapies for patients with myocardial diseases will require not only understanding of the functional pluralism of cardiac fibroblasts and dissection of the molecular basis for fibrotic remodelling, but also appreciation of the pathophysiologic heterogeneity of fibrosis-associated myocardial disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inflammation and tissue fibrosis co-exist and are causally linked to organ dysfunction1,2.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [2]
In the citing paper
“Among stromal cell types, fibroblasts are of particular interest given their role in tissue fibrosis, arrhythmias, and heart failure 16,29,30 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [30]
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495 · cited 1×
“Fibrosis is an important cause of organ dysfunction in many different diseases, including interstitial lung diseases, liver cirrhosis, progressive systemic sclerosis, and diabetic nephropathy.(1)”
BackgroundMyofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Obesity and the risk of heart failure
Kenchaiah, S., Evans, J. C., Levy, D., Wilson, P. W. F., Benjamin, E. J., Larson, M. G., Kannel, W. B., & Vasan, R. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020245 · Cited by 3,093
Ignotz, R. A., & Massagué, J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35666-1 · Cited by 2,492
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis
Prabhu, S. D., & Frangogiannis, N. G. (2016) · Circulation Research · doi:10.1161/circresaha.116.303577 · Cited by 2,224
Self-citationEndothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222 · cited 2×
“The antifibrotic effects were attributed to blockade of TGF-b signalling and were associated with attenuated endothelial to mesenchymal transition.(22,247) Moreover, gain-of-function studies have”
BackgroundHinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
Cited by
Items 701–800 of 1,000
Sridhar, K. C., Mehl, J., Klingel, K., Thiele, M., Linthout, S. V., Tschöpe, C., Duda, G. N., & Viola Vogel, B. (2025) · Matrix Biology Plus · doi:10.1016/j.mbplus.2025.100182 · Cited by 5
“As unresolved inflammation often results in progressive fibrosis and scar tissue formation [12,13], second harmonic generation (SHG) microscopy was performed to detect the presence of collagen I/III fibers and hence the onset of fibrosis.”
The pathophysiological mechanisms of immunosenescence in coronary artery disease
Bie, H., & Tao, Z. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1686947 · Cited by 4
“Accumulating ROS both drives senescence and reinforces immune dysfunction, creating a feed-forward loop (Frodermann and Nahrendorf, 2018; Frangogiannis, 2021).”
Lotfollahzadeh, S., Paul, H., Bonifacio, J., Almiron, R., Hoekstra, I., Przekop, K. A., Yamamoto, T., Piqueras, M. D. C., Yin, W., Sethuraman, K., et al. (2025) · Kidney360 · doi:10.34067/kid.0000000900 · Cited by 4
LncRNA SNHG8 promotes myocardial fibrosis by binding to E2F1 to induce MAD2L1 transcription
Huang, L. H., Liu, C., Zhao, Z., Xie, S., Sun, Z., Liao, X., Bian, X., Liu, X., Ren, X., & Wang, N. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148362 · Cited by 4
Baufays, C., Cumps, J., Dufeys, C., Ginion, A., Bertrand, L., Horman, S., Beauloye, C., & Marino, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010098 · Cited by 5
“Furthermore, while fibroblasts are the primary source of extracellular matrix proteins, other cell types such as immune cells, vascular cells, and cardiomyocytes also play a major role in the development of fibrosis [31].”
InfluentialScarred by Fibrosis: The Heart–Kidney Disease Connection
Boukhaled, J. H., Martin, E. J., Gayrard, N., Argilés, À., Karsdal, M. A., & Genovese, F. (2025) · Annual Review of Physiology · doi:10.1146/annurev-physiol-043024-115512 · Cited by 5
Mechanisms and Therapies of Hypertrophic Cardiomyopathy
Pietsch, N., Singh, S. R., & Carrier, L. (2025) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042224-093244 · Cited by 4
Aging hearts, fibrotic fears: The sirtuin connection
Grzeczka, A., Graczyk, S., Gong, X., Gröschel, J., Spethmann, S., & Kordowitzki, P. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118882 · Cited by 5
Zhang, M., Meng, X., Yang, Y., Chen, X., Wang, Y.-C., Wan, J., Ding, J., Wang, B., Peng, K., & Ji, F. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.113825 · Cited by 5
Zhang, Q., Chen, J., Zhou, L.-N., Wu, X.-F., Wu, Y.-Z., Li, W.-T., Xia, G.-Y., Xia, H., Shang, H.-C., Wei, X.-H., et al. (2025) · Pharmaceutical Biology · doi:10.1080/13880209.2025.2602234 · Cited by 4
“This activation leads to the phosphorylation of downstream Smad2/ Smad3 signaling by binding to surface receptors, thereby initiating a fibrogenic signaling cascade (Frangogiannis 2021).”
Unraveling Cardiovascular Development and Function: Insights From Single-Cell Omics
Harper, R. L., Lelliott, P. M., Bender, S. B., & Pinto, A. R. (2026) · Circulation Research · doi:10.1161/circresaha.125.325793 · Cited by 4
Fibroblast circSamd4 promotes cardiac fibrosis via activating plasminogen activator inhibitor-1
Chen, Y., Zhang, Z., Cheng, Y., Chen, X., Zhou, J., Wei, Z., Yao, H., Zhang, S., Kong, Q., Tang, H., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104018 · Cited by 4
“However, it remains a formidable challenge in cardiovascular medicine owing to the lack of effective pharmacotherapies [1 – 3].”
Peng, Y., Wei, J., & Yang, Y. (2026) · Antioxidants · doi:10.3390/antiox15020219 · Cited by 5
“These structural and functional alterations compromise myocardial mechanics and metabolic flexibility, ultimately leading to pump failure [3].”
Periostin contributes to differential sex-linked gene expression during infarct healing
Abual’anaz, B. M., Cayer, L. G. J., Rasul, S. S. H., Rattan, S. G., Lambos, J. C., Evans, T. I. M., Rabinovich-Nikitin, I., Kirshenbaum, L. A., Kienesberger, P. C., Wigle, J. T., et al. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00675.2025 · Cited by 4
Lactylation Modification: From Basic Biological Process to Clinical Cardiovascular Diseases
Geng, J., Fang, Z., Zhang, Z., Ge, J., & Li, H. (2026) · Research · doi:10.34133/research.1228 · Cited by 4
Dai, S., Li, B., Zhang, Z., Zhang, G., & Guo, S. (2026) · Journal of Thoracic Disease · doi:10.21037/jtd-2026-1-0099 · Cited by 4
Świątko, M., Baran, J. M., Czernicka, A., Dudek, Ł., Szewczyk, M., Pietruszka, J., Łazarowicz, Ł., Kochman, W., & Dziedzic, E. A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103742 · Cited by 4
“Deposition of cross-linked collagen within the interstitium and vascular walls contributes to diastolic dysfunction and is considered a key mechanism in HFpEF, where increased myocardial stiffness and impaired relaxation often precede overt clinical deterioration [55].”
Matrifibrocytes Redefine Cardiac Fibrosis: From Terminal Differentiation to Translational Modulation
Zhang, Z., & Zhu, H. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71174 · Cited by 4
Nguyen, D. C., Stephan, J., Luque, L. G., Brainard, R. E., Brittian, K. R., Wells, C., Teer, M. S., Martinez‐Ondaro, Y., Gouwens, K. R., Little, D. T., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73646-4 · Cited by 4
Hu, X., Chen, M., Cao, X., Yuan, X., Zhang, F., & Ding, W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.917719 · Cited by 4
“5 Exposure Cytokines, including TNF-α, TGF-β, and IL-6, play remarkable roles in cardiac fibrosis, which combined with fibroblast surface receptors to activate fibrosis-related signal pathways (18, 19).”
BackgroundXin, J.-J., Gao, J.-H., Liu, Q., Zhao, Y.-X., Zhou, C., & Yu, X.-C. (2022) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-022-2897-0 · Cited by 4
“Activation of immune pathways and induction of pro-inflammatory signaling are associated with fibrosis.((2)) IL-1β is one of the main pro-inflammatory cytokines that delays myofibroblast conversion, and modulates fi broblast phenotype.”
BackgroundWang, J., Chen, X., Zhang, L., Zheng, Y., Qian, J., Sun, N., Ding, X., & Cui, B. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1042852 · Cited by 4
“Particularly, immune responses at early phase are associated with cardiac remodeling after injury (5, 6).”
BackgroundBabaei, G., Sadraei, S., Yarahmadi, M., Omidvari, S., Aarabi, A., & Rajabibazl, M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09371-2 · Cited by 4
“Cardiac fibrosis is a pathological process that occurs in most heart diseases, including hypertensive heart disease, myocardial infarction, and various cardiomyopathies [43, 44].”
Early- to mid-gestational testosterone excess leads to adverse cardiac outcomes in postpartum sheep
Alkhatib, B., Ciarelli, J. N., Ghnenis, A. B., Pallas, B. D., Olivier, N. B., Padmanabhan, V., & Vyas, A. K. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00763.2023 · Cited by 4
Novel Mouse Model for Selective Tagging, Purification, and Manipulation of Cardiac Myofibroblasts
Janbandhu, V. C., Tallapragada, V. J., Li, J. V., Shewale, B., Ghazanfar, S., Patrick, R., Cox, C. D., & Harvey, R. P. (2024) · Circulation · doi:10.1161/circulationaha.123.067754 · Cited by 4
Lu, Y., Yang, S., Yang, Q., & Huang, W. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400383 · Cited by 4
Advancing 3D Engineered In Vitro Models for Heart Failure Research: Key Features and Considerations
van Doorn, E. C. H., Amesz, J. H., Manintveld, O. C., de Groot, N. M. S., Essers, J., Shin, S. R., & Taverne, Y. J. H. J. (2024) · Bioengineering · doi:10.3390/bioengineering11121220 · Cited by 4
Liang, H., Huang, S., Xu, X., Yin, Z., Hussain, M., Song, X., Yi, J., He, Y., Guo, J., Tu, Z., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00087 · Cited by 4
Li, X., Jiang, S., Yang, W., Zhu, X., Zhang, F., Li, Z., Guo, X., & Wei, Y. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.02.014 · Cited by 4
Adamts1 Exacerbates Post‐Myocardial Infarction Scar Formation via Mechanosensing of Integrin α8
Kong, C., Guo, Z., Ma, Y., Wang, M., Ni, H., Wang, P., Qiu, W., Wang, E., Li, Z., Zheng, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202504138 · Cited by 4
Chen, X., Liu, G., Zheng, Z., Fu, R., Song, Y., & Dou, K. (2025) · iScience · doi:10.1016/j.isci.2025.113692 · Cited by 4
Treatment of Cardiac Fibrosis with Extracellular Vesicles: What Is Missing for Clinical Translation?
Neuber, S., Ermer, M. R., Emmert, M. Y., & Nazari‐Shafti, T. Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310480 · Cited by 4
“A central factor in the progression from acute myocardial infarction to chronic or terminal heart failure is cardiac fibrosis, which is characterized by extensive remodeling of the myocardial extracellular matrix (ECM) [2].”
BackgroundInfluentialZhu, S., Bai, L., Pan, Y., Yin, J., Zhang, D., Hou, C., Wang, Y., & Li, R. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.86210 · Cited by 4
Bao, H., Zhang, Y., Xin, H., Gao, Y., Hou, Y., Yue, G., Wang, N., Wang, Y., Li, C., Liu, F., et al. (2024) · ACS Omega · doi:10.1021/acsomega.3c06628 · Cited by 4
“25,26 The elastic membrane in natural blood vessels plays an instrumental role in preventing excessive expansion under high blood pressure conditions.”
BackgroundMyocardial fibrosis in right heart dysfunction
Agoşton-Coldea, L., & Negru, A. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.02.005 · Cited by 4
Effects of gas signaling molecule SO2 in cardiac functions of hyperthyroid rats
Yang, Q., Yang, T., Liu, X., Liu, S., Liu, W., Nie, L., Chu, C., & Yang, J. (2024) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2024.28.2.129 · Cited by 4
Li, Z., Peng, X., Zhu, X., Spanos, M., & Wu, L. (2024) · Pharmacology · doi:10.1159/000540915 · Cited by 4
Inorganic Polyphosphate Is in the Surface of Trypanosoma cruzi but Is Not Significantly Secreted
Crowe, L. P., Gioseffi, A., Bertolini, M. S., & Docampo, R. (2024) · Pathogens · doi:10.3390/pathogens13090776 · Cited by 4
“Neither the T. cruzi trypomastigote-conditioned medium nor synthetic polyP were able to induce TGF-β activation, a reported mediator of cardiac fibrosis [14].”
BackgroundTalle, M. A., Robbertse, P. S., Doubell, A. F., Lahri, S., & Herbst, P. G. (2024) · Scientific Reports · doi:10.1038/s41598-024-74099-9 · Cited by 4
Li, R., Li, X., Zhang, X., Yu, J., Li, Y., Ran, S., Wang, S., Luo, Z., Zhao, J., Hao, Y., et al. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.11.018 · Cited by 5
Abidi, E., Diab, R., Zahreddine, R., Amin, G., Kaplan, A., Booz, G. W., & Zouein, F. A. (2024) · Biology of Sex Differences · doi:10.1186/s13293-024-00667-3 · Cited by 4
“IL-4 and IL-13 are associated with cardiac fibrosis and hypertrophy [29–31], while IL-1β mediates inflammation, endothelial dysfunction and myocardial injury [32].”
Qu, Y., Ma, D., Wu, T., Wang, H., Tian, Z., Liu, X., & Wang, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-81611-8 · Cited by 6
Xu, Z., Yang, J., Hu, Y., Wan, Q., Wang, X., Lu, C. Y., & Liu, Y. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119229 · Cited by 4
Zhang, J., Wang, W., Wang, Z., Zhou, M., & Wu, S.-B. (2025) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-025-03404-y · Cited by 4
Zhou, X., Prothon, S., Engin, L., Ferrari, N., Hezaveh, K., Liu, Z., Nemes, S., Almquist, J., Williams, M. L., Sobande, O., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112602 · Cited by 4
Yang, B., Rutkowski, N., Ruta, A., Gray-Gaillard, E. F., Maestas, D. R., Kelly, S. H., Krishnan, K., Wu, X., Wu, S., Chen, A. R., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2422169122 · Cited by 5
Beyond conventional therapy: NOX4 as a promising target in cardiomyopathy
Dubey, N., Chaturvedi, G., Singh, S., Chauhan, A., Panchbhai, P., Narang, R., Parakh, N., Goyal, A., & Yadav, H. N. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10818-3 · Cited by 4
Mohr, T., Schiffer, M., Ramanujam, D. P., Carls, E., Zgierski-Johnston, C. M., Kok, T., Niemann, P., Geisen, C., Köhl, P., Engelhardt, S. H., et al. (2025) · The Journal of Physiology · doi:10.1113/jp288020 · Cited by 5
Shi, C., Zhang, H., Zhang, N., Liu, D., Fan, Z., Sun, Z., Liu, J., & Xu, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154262 · Cited by 4
Kimball, T. H., Gromova, T., Gehred, N., Chapski, D. J., Wang, K., Vaseghi, M., Fischer, M. A., Lefer, D. J., & Vondriska, T. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.11.617933 · Cited by 4
Schmidt, C. E., & Müller, H. D. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102976 · Cited by 4
RetractedDeletion of PIEZO1 in adult cardiomyocytes accelerates cardiac aging and causes premature deathPreprint
Yu, Z., Guo, Y., Kesteven, S. H., Cheng, D., Lei, H., Wu, J., Nadar, E. I., Macdonald, P. S., Xaymardan, M., Cox, C. D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.20.633994 · Cited by 4
Titin cleavage is a driver of cardiomyocyte disengagement and reactive myocardial fibrosisPreprint
López-Unzu, M. Á., Pricolo, M. R., Silva‐Rojas, R., Clemente-Manteca, A., Sánchez-Ortiz, D., Vicente, N., Velázquez-Carreras, D., Morales, C., Gavilán-Herrera, M., Sen-Martín, L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.22.645683 · Cited by 4
Targeting RUNX1 in Macrophages Facilitates Cardiac RecoveryPreprint
Amrute, J., Zhu, A., Pai, Y.-L., Hector-Greene, M., An, Y., Kim, K. R., Sheth, M. U., Padmanabhan, A., Lee, C. Y., Yamawaki, T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.25.665779 · Cited by 8
Clinical development complexity of TGF-β inhibition: From fibrosis to cancer immunotherapy
Gallo-Oller, G., Guillén-Antonini, M. I., & Dotor, J. (2025) · International review of cytology · doi:10.1016/bs.ircmb.2025.01.005 · Cited by 3
Particulate matter induces activation of cardiac fibroblasts via HIF1α-mediated autophagy
Wang, Z., Hong, G., Dou, R., Yan, L., Chen, S., Lin, Z., Ye, X., Zhang, Z., Shen, Q., Du, J., et al. (2025) · Environmental Sciences Europe · doi:10.1186/s12302-025-01082-0 · Cited by 3
“Fibroblasts serve as central cellular effectors in cardiac fibrosis [53].”
Research Progress on Anti-fibrotic Effects and Mechanisms of Tetrandrine
Ma, P., Cai, Y.-J., Dong, H., & Dong, R.-L. (2025) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-025-4130-4 · Cited by 3
“(102) TGF-β produced by myofibroblasts is one of the most potent pro fi brogenic mediators and a primary stimulator of collagen production in cardiac fibrosis.”
SPaSE: Spatially resolved pathology scores using optimal transport on spatial transcriptomics data
Rahman, M. N., Abrar, M. A., Shaw, V. R., Martin, J. F., Rahman, M. S., & Samee, M. A. H. (2025) · Cell Systems · doi:10.1016/j.cels.2025.101301 · Cited by 6
Azeredo, P. D. S., Fix, C., Pernomian, L., Wenceslau, C. F., Piroli, G. G., Vicente, C. P., & Carver, W. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26135964 · Cited by 3
“A major hallmark of many cardiovascular diseases is myocardial remodeling, often accompanied by cellular dysfunction and alterations in extracellular matrix (ECM) dynamics, which may contribute to pathological outcomes such as fibrosis and heart failure [2–4].”
Extracellular Aldehyde Sensing Probes for In Vivo Imaging
Ning, Y., Akam, E. A., & Caravan, P. D. (2025) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5c00200 · Cited by 3
Research Progress of Sodium Alginate-Based Hydrogels in Myocardial Infarction Treatment
Chen, Z., Lan, X., Zhu, E., Liu, J., & Zhang, C. (2025) · Tissue Engineering Part B Reviews · doi:10.1177/19373341251364282 · Cited by 3
Advances in fibroblast-based cardiac reprogramming in the treatment of heart disease
Jin, Y., Liu, Y., Ge, A., Yang, Y. P., Wan, Y., Li, C., & Zhang, C. (2025) · Inflammation Research · doi:10.1007/s00011-025-02079-4 · Cited by 3
“For example, myocardial infarction (MI), ischemia–reperfusion injury (IRI), heart failure (HF), and cardiac hypertrophy are specific categories of diseases that lead to death from heart disease, all of which result in irreversible cardio - myocyte death and cardiac fibrosis [ 2 ].”
Arrhythmogenic Cardiomyopathy and Biomarkers: A Promising Perspective?
Barocelli, F., Pasini, N., Bettella, A., Crocamo, A., Ambrosini, E., Gurgoglione, F. L., Canu, E., Triglia, L. T., Russo, F., Guidorossi, A., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14197046 · Cited by 3
Advances in cardiac cell interaction studies: Implications for heart disease treatment
Huang, L., Xie, B., Xiang, A. P., & Xiang, Q. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112161 · Cited by 4
Zuo, Y., Yang, S., Qian, X., & Liu, K. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1668586 · Cited by 3
“Notably, Il6 levels are not only indicative of myocardial injury but also show a strong association with acute myocardial infarction (Frangogiannis, 2021).”
Bentele, M., Linke, S., Neumüller, S., Korte, A., Gietz, A., Just, A., Stucki-Koch, A., Pfanne, A., Liu, J., Zhao, J., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-28222-z · Cited by 3
Huang, W., Wang, X., Yan, X., Wang, S., Lin, L., Li, L., Liu, L., Wang, Y., Li, X., Mao, Y., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.157783 · Cited by 3
The role of free‐fatty acid receptors FFA1 and FFA4 in organ fibrosis
Karmokar, P. F., & Moniri, N. H. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70334 · Cited by 4
“Myocardial fibrosis is characterised by the expansion of the cardiac interstitium because of the excessive accumulation of ECM proteins, which contributes to the progression of various myocardial disorders and ultimately leads to heart failure (Frangogiannis, 2021).”
Pannexins in the heart: cell-specific expression and contributions to disease
Renton, M. C., Sedovy, M. W., Reynolds, A., Hoch, A., Roberts, K., Sarmiento, R., Toler, C. O., & Johnstone, S. R. (2026) · Cell and Tissue Research · doi:10.1007/s00441-026-04046-9 · Cited by 3
“Cardiac fibrosis, characterized by deposition and remodeling of the cardiac extracellular matrix, is a consequence of both ischemia/reperfusion injury and non-ischemic heart failure and leads to impaired contractility and relaxation (Frangogiannis 2021).”
Jin, C., Shao, C., Xu, G., & Wan, H. (2026) · Biology · doi:10.3390/biology15020206 · Cited by 3
Feng, K., An, J., Zhang, X., Li, G., Ruan, Y., Huang, H., Sun, Y., Liu, X., & Sun, X. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202505502 · Cited by 3
“ThecomplexpathologicalcharacteristicsofMIinclude the apoptosis of cardiomyocytes [9, 10], the lasting inflammation of immune cells [11–13], fibrosis mediated by activated fibroblasts [14, 15], and impaired vascular endothelial cells [16, 17].”
Role of Scar‐Associated Macrophages in Organ Fibrosis Diseases
Ding, R., Yang, Z., Chen, Y., Yu, Q., Ji, Y., Wang, Z., & Gu, M. (2026) · Journal of Immunology Research · doi:10.1155/jimr/8393673 · Cited by 3
“Cardiac fi brosis is characterized by the accumulation of ECM proteins in the cardiac interstitium, leading to systolic and diastolic dysfunction under various cardiac pathophysiological conditions [65, 66].”
Effects of arginine vasopressin deficiency on cardiac fibrosis in male Wistar rats
Limón‐Mendoza, A., Alamilla‐Rasso, J., González‐Nuñez, S., Becerra‐Mendez, M., García‐Álvarez, S., Tinajero‐Vidales, K., Tinajero‐Ruelas, M., & Quintanar‐Stephano, A. (2026) · Physiological Reports · doi:10.14814/phy2.70748 · Cited by 3
“…into active myofibroblast; this process is regulated by angiotensin II (AT1R), aldosterone (MAPK pathway), transforming growth factor beta (TGF-β ), mechanical distention through mechanosensitive channels, and proinflammatory cytokines (IL-6, IL-11, and endothe- lin-1) (Frangogiannis, 2021).”
InfluentialGuo, Z., Wang, J., Xia, L., Gong, X., Zhou, X., Sun, Y., Xia, Y., Tan, R., Yuan, J., & Zhang, G. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl42697 · Cited by 3
Composition and Influence of Fibrogenic Niche in Myocardial Fibrosis
Wang, X., Fan, L., Yuan, Q., Luo, Y., Cheng, Z., Chen, Y., & Gong, C. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44112 · Cited by 3
“…inflammatory responses and tend to stimulate immunocompetent cells [28], as well as C-C motif chemokine ligand 2 (CCL2), transforming growth factor-β (TGF-β ), Wingless-type MMTV integration site family (Wnt), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) [6,29,30].”
Huang, F., Zhou, M., Chen, Y., Hua, S., Han, Y., Fan, Y., Li, Q., Sun, Z., Yang, K., Zhao, Q., et al. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag036 · Cited by 3
Krzyżewska, A., Baranowska‐Kuczko, M., & Kozłowska, H. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70347 · Cited by 3
“As mentioned above, CFs are generally considered to be the main (but not the only) cells regulating ECM production in the heart, which are activated and transformed into myofibroblasts in response to damaging factors via neurohormonal and mechanosensitive pathways or growth factors (Frangogiannis, 2020; Maruyama & Ima…”
InfluentialWu, J., Zhao, C., Li, X., Guo, X., Tan, W., Zhou, L., Zhang, Y., Zhang, J., Zheng, S., Zeng, C., et al. (2026) · Phytotherapy Research · doi:10.1002/ptr.70248 · Cited by 3
Myocardial fibrosis and glycolysis: a bibliometric study and visualization analysis (2000–2024)
Chen, Q., Ye, X., Shu, C., Ren, C., Wang, X., Jiang, H., Zhi, X., Li, L., Li, Q., Liu, K., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08005-4 · Cited by 3
“Although treatments such as renin– angiotensin system inhibitors and anti-inflammatory therapies have shown some progress, their clinical efficacy remains limited, and the long-term prognosis for patients remains poor [15].”
Kontaraki, J. E., Plevritaki, A., Sallo, A., Fragkiadakis, K., Kallergis, E. M., Zacharis, E. A., Kopidakis, J. K., Kampanieris, E., Achladianaki, S. A., Papakosta, V., et al. (2026) · Genes · doi:10.3390/genes17030356 · Cited by 3
“Non-canonical TGF-β signaling activates MAPK pathways—namely ERK, c-Jun N-terminal kinase (JNK), and p38 MAPK—thereby reinforcing fibroblast activation and promoting extracellular matrix gene expression [49].”
Kumagai, K., Kawamura, T., Torigata, K., Harada, A., Kishimoto, Y., Miyagawa, S., & Yoshikawa, Y. (2026) · Regenerative Therapy · doi:10.1016/j.reth.2026.101105 · Cited by 3
“Excessive myocardial fibrosis is considered a key factor in reducing myocardial contractility and causing diastolic dysfunction, thereby increasing the mortality rate in patients with heart failure [4].”
Cardiac fibroblast heterogeneity in cardiac fibrosis implication for cell-type-specific treatment
Gu, K., Song, D., & Chen, J. H. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1740147 · Cited by 3
“These mechanical and neurohormonal insults converge on a state of chronic, low-grade inflammation, which perpetuates the fibrotic response (Frangogiannis, 2021).”
Zhao, J., Ruan, Y.-E., Chen, Y., Chen, Q., Hong, T., Wang, L. Y., Xu, Y., Hou, L., Liao, F., Yin, D., et al. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag119 · Cited by 3
Neurotensin receptor 2 agonism attenuates adverse cardiac remodeling in preclinical models
Shiva, N., Kawase, H., Einsiedel, J., Kwon, J., Kumar, S., Shao, J., Du, Z., Kubin, N., Shimari, M., Günther, S., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aea9877 · Cited by 3
Grigoriou, K., Lamprou, V., Antoniadis, A. P., Theofilis, P., Iliakis, P., Ktenopoulos, N., Apostolos, A., Nasoufidou, A., Fyntanidou, B., Karagiannidis, E., et al. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl48667 · Cited by 3
Myocardial Immune Niches in Homeostasis and Inflammation
Perez‐Shibayama, C., Cadosch, N., Schmidt, D., Flammer, A. J., Ruschitzka, F. T., Gil‐Cruz, C., & Ludewig, B. (2026) · Immunological Reviews · doi:10.1111/imr.70139 · Cited by 4
Zhang, Z., Lang, X., Zhang, Y., Dong, X., Han, X., Ch, X., & Zhuang, X. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146464 · Cited by 4
“Ultimately, persistent mechanical imbalance and chronic neurohormonal overload maintain myofibroblast activation, promoting the spread of pathological interstitial fibrosis into non-infarcted regions and inducing myocardial hypertrophy [17].”
Wilson, T. D., Phillips, E. A., Alharithi, Y. J., Broberg, C., Vanderpool, J., Rakshe, S. K., Fei, S. S., Davis, B. A., Koch, S. E., Zhu, Z., et al. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00507.2026 · Cited by 3
Impact of ischemia on left atrial remodeling and dysfunction in swine models of mitral regurgitation
Sakata, T., Mazurek, R., Mavropoulos, S. A., Romeo, F. J., Ravichandran, A. J., Watanabe, S., Kariya, T., & Ishikawa, K. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00009.2022 · Cited by 3
Hidalgo, V., Kastury, N., Durham, C. W., Currie, J., Amaya, M., Lam, M. P. Y., & Lau, E. (2023) · PubMed Central · doi:10.17912/micropub.biology.000864 · Cited by 3
Beikzadeh, B., Khani, M., Zarinehzadeh, Y., Bakhshmand, E. A., Sadeghizadeh, M., Rabbani, S., & Soltani, B. M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311817 · Cited by 3
Exosome-Derived microRNAs in Hypertrophic Cardiomyopathy
Wang, B. (2024) · Cardiogenetics · doi:10.3390/cardiogenetics14040019 · Cited by 4
“One form of fibrosis is interstitial fibrosis, where there is excessive deposition of collagen and other extracellular matrix proteins between cardiomyocytes [19].”
Limyati, Y., Lucretia, T., Gunadi, J. W., Vitriana, V., Jasaputra, D. K., Wahyudi, K., & Lesmana, R. (2025) · Biomedical Reports · doi:10.3892/br.2025.1922 · Cited by 3
Feng, X.-Y., Zheng, Y., Yang, Y., He, W., Yang, F., Wang, L.-L., Yang, H., Li, C., Xu, X., & Li, R. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25654 · Cited by 3
Cardiac protection of wogonin in mice with pulmonary fibrosis by regulating Sirt1/ γ-H2AX pathway
Wang, L., Lin, F., Miao, R., Zhao, T., Liu, Y., Yang, L., & Zhang, M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1551141 · Cited by 5
“Evidence strongly suggests that myocardial fi brosis independently drives the development of cardiac dysfunction, ultimately leading to HF (Frangogiannis, 2021; López et al., 2021).”
piRNA, the hidden player in cardiac fibrosis: A review
Li, Y., Fang, B., He, Y., Wang, Y., Wang, K., & Yang, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.146437 · Cited by 3
Shu, C., Ren, C., Chen, Q., Wang, Y., Li, R., Zhang, Y., Yang, S., Wang, C., & Li, Y. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1627255 · Cited by 3
Hays, H., & Richardson, W. A. (2026) · Matrix Biology Plus · doi:10.1016/j.mbplus.2026.100195 · Cited by 3
“…extending beyond initially stimulated regions demonstrates how localized inflammatory or mechanical stimuli can propagate across tissue domains through paracrine signaling mechanisms, consistent with recent experimental observations of fibrotic spread following myocardial infarction [42,43].”
Tao, M., Mao, J., Wang, G., Jiang, Y., Li, G., Zhang, K., Sun, L., & Yang, G. (2026) · Food & Function · doi:10.1039/d5fo04185f · Cited by 4
Yao, T., Yang, H., Sun, J., Zhang, Y., Zhang, Y., Song, Q., Liu, W.-Z., Zhang, J., & Li, A. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/6841276 · Cited by 3
“e increase in ventricular stiness caused by collagen deposition is closely related to many harmful outcomes, such as heart failure and even cardiac death [2].”
Background
Metadata
- Authors
- Frangogiannis, N. G.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Frangogiannis, Nikolaos G
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-02
- Volume
- 117
- Issue
- 6
- Pages
- 1450-1488
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- PMC
- PMC8152700
- OpenAlex
- W4210607007
- Cited by
- 1,229
- References
- 615
- Citations by year
- 2026: 265 · 2025: 319 · 2024: 273 · 2023: 210 · 2022: 130 · 2021: 32
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Cardiovascular Research (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH (R01 HL76246, R01 HL85440, R01 HL149407)
- U.S. Department of Defense (PR151134, PR151029, PR181464)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- myocardial fibrosis, myocardial fibroblasts, myofibroblasts, extracellular matrix deposition, TGF-beta, platelet-derived growth factor, cytokines, mechanoreceptors, integrins, pressure overload, myocardial infarction, heart failure, familial cardiomyopathy, diabetic cardiomyopathy, cardiac arrhythmias
- MeSH terms
- Antifibrotic Agents, Animals, Extracellular Matrix, Fibroblasts, Fibrosis, Humans, Cardiomyopathies, Myocytes, Cardiac, Mechanotransduction, Cellular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.